p53 immunohistochemical expression and patient prognosis in esophageal squamous cell carcinoma

被引:0
作者
Asuka Murata
Yoshifumi Baba
Masayuki Watanabe
Hironobu Shigaki
Keisuke Miyake
Ryuichi Karashima
Yu Imamura
Satoshi Ida
Takatsugu Ishimoto
Shiro Iwagami
Yasuo Sakamoto
Yuji Miyamoto
Naoya Yoshida
Hideo Baba
机构
[1] Kumamoto University,Department of Gastroenterological Surgery, Graduate School of Medical Science
来源
Medical Oncology | 2013年 / 30卷
关键词
p53; Esophageal squamous cell carcinoma; Prognosis; IHC;
D O I
暂无
中图分类号
学科分类号
摘要
It is generally accepted that overexpression of p53 protein is associated with poor prognosis in gastric, lung, and other types of cancer. However, the prognostic significance of p53 aberrations in esophageal cancer remains unclear. This is the largest study (n = 266) examining clinical and prognostic features of p53 immunohistochemical expression in esophageal squamous cell carcinoma. In 139 (52 %) esophageal tumors, nuclear immunoreactivity for p53 protein was detected. p53 aberrant expression was not associated with sex, age, preoperative treatment, TNM stage, or histological grade. Furthermore, p53 expression did not correlate with disease-free survival (P = 0.73) or overall survival (P = 0.62). In addition, no significant modification effect by any of the covariates in the survival analysis was observed (all P > 0.15). In conclusion, our large-scale study demonstrates that p53 expression has no impact on the prognosis of esophageal squamous cell carcinoma.
引用
收藏
相关论文
共 305 条
  • [1] Enzinger PC(2003)Esophageal cancer N Engl J Med 349 2241-2252
  • [2] Mayer RJ(2010)Optimum lymphadenectomy for esophageal cancer Ann Surg 251 46-50
  • [3] Rizk NP(2009)Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer J Clin Oncol 27 5062-5067
  • [4] Ishwaran H(2011)Long-term outcome of 2920 patients with cancers of the esophagus and esophagogastric junction: evaluation of the New Union Internationale Contre le Cancer/American Joint Cancer Committee staging system Ann Surg 253 689-698
  • [5] Rice TW(2010)The prognostic and chemotherapeutic value of miR-296 in esophageal squamous cell carcinoma Ann Surg 251 1056-1063
  • [6] Chen LQ(2009)Genetic variations in the PI3 K/PTEN/AKT/mTOR pathway are associated with clinical outcomes in esophageal cancer patients treated with chemoradiotherapy J Clin Oncol 27 857-871
  • [7] Schipper PH(2009)The first 30 years of p53: growing ever more complex Nat Rev Cancer 9 749-758
  • [8] Kesler KA(2009)Blinded by the light: the growing complexity of p53 Cell 137 413-431
  • [9] Allum WH(1994)Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis Cancer Res 54 4855-4878
  • [10] Stenning SP(1994)p53 in tumour pathology: can we trust immunohistochemistry?–Revisited! J Pathol 172 1-4